Nonsteroidal selective androgen receptors modulators (SARMs): Designer androgens with flexible structures provide clinical promise

Endocrinology

Volumn 145, Issue 12, 2004, Pages 5417-5419

  Brown, Terry R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; MEGESTROL ACETATE; NILUTAMIDE; RALOXIFENE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

DNA SEQUENCE; DRUG DESIGN; DRUG INDICATION; DRUG STRUCTURE; DRUG USE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; RECEPTORS, ANDROGEN;

EID: 9444285918     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1207     Document Type: Short Survey

References (33)

1. Migeon CJ, Berkovitz GD, Brown TR 1994 Sexual differentiation and ambiguity. In: Kappy MS, Blizzard RM, Migeon CJ, eds. The diagnosis and treatment of endocrine disorders in childhood and adolescence. Springfield, IL: Charles C Thomas Publisher; 573-715
2. Mooradian AD, Morley JE, Korenman SG 1987 Biological actions of androgens. Endocr Rev 8:1-28
3. Chang C, Kokontis J, Liao S 1988 Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326
4. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM 1988 Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327-330
5. Bagatell CJ, Bremner WJ 1996 Androgens in men - uses and abuses. N Engl J Med 334:707-714
6. Nieschlag E, Behre H 1998 Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre H, eds. Testosterone: action, deficiency, substitution. Berlin: Springler-Verlag; 293-328
7. Neumann F, Topert M 1986 Pharmacology of antiandrogens. J Steroid Biochem 25:885-895
8. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-213
9. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT 2004 Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145:5420-5428
10. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD 1998 Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4
11. Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stounnan N, Kirkovsky L, Miller DD, Dalton JT 2003 Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 63:211-223
12. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT 2003 Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 304:1334-1340
13. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD 2004 Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem 47:993-998
14. Zhi L, Martinborough E 2001 Selective androgen receptor modulators (SARMs). Annu Rep Med Chem 36:169-180
15. Zhi L, Tegley CM, Marschke KB, Jones TK 1999 Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g] quinolinone. Bioorg Med Chem Lett 9:1009-1012
16. Kong JW, Hamann LG, Ruppar DA, Edwards JP, Marschke KB, Jones TK 2000 Effects of isoteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-trifluoromethyl-8- pyridono[5,6-g]quinolines. Bioorg Med Chem Lett 10:411-414
17. Mayachi H, Azuma A, Kitamoto T, Hyashi K, Kato S, Koga M, Sato B, Hashimoto Y 1997 Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton. Bioorg Med Chem Lett 7:1483-1488
18. Negro-Vilar A 1999 Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84:3459-3462
19. Allan GF, Sui Z 2003 Therapeutic androgen receptor ligands. NURSA e-Journal 1:ID# 3.09172003.09172001
20. Glen AT, Hughes LR, Morris JJ, Taylor PJ 1986 Structure-activity relationships among nonsteroidal antiandrogens. In: Lambert RW, ed. Proceedings of the third Sci-RSC medicinal chemistry symposium. London: Royal Society of Chemistry; 345-361
21. Tucker H, Crook JW, Chesterson GJ 1988 Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J Med Chem 31:954-959
22. Yin D, Xu H, Kirkovsky LI, Miller DD, Dalton JT 2003 Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther 304:1323-1333
23. Kallio PJ, Janne OA, Palvimo JJ 1994 Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. Endocrinology 134:998-1001
24. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization - studies on the mechanism of antiandrogen action. J Biol Chem 270:27569-27576
25. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Marcedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor: implications for pathogenic gene mutations. J Biol Chem 275:26164-26171
26. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffer JE, Salvati ME, Krystek SR, Weinmann R, Einspahr HM 2001 Crystallographic structures of the ligand binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904-4909
27. Jenster G, van der Korput JAGM, Trapman J, Brinkmann AO 1995 Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270:7341-7346
28. Doesburg P, Kuil CW, Berrovoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052-1064
29. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225
30. He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
31. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 12:1172-1183
32. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13:440-454
33. He B, Bowen NT, Minges JT, Wilson EM 2001 Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293-42301